Smitha P. Menon, MBBS

Smitha Menon practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Smitha Menon's NPI, 1487627253, was assigned on February 10, 2006. Smitha Menon holds Washington license MD61357298.

Smitha Menon's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Smitha Menon's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Smitha Menon is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians. Dmand AI also links Smitha Menon to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Smitha Menon practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Smitha Menon's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Smitha Menon's licenses on file in 3 states: Washington, Minnesota and Wisconsin.

CMS data shows 539 Medicare services from Smitha Menon across 7 procedure codes in 2024, for 99 Medicare patients. Medicare paid $42,608 for them.

CMS counts 99 Medicare patients who saw Smitha Menon in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have cancer, and 61% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Smitha Menon's median patient age at 70, with 58% women.

In 2024, Smitha Menon wrote 272 Medicare Part D claims for 43 patients. 80% of them were for generic drugs. CMS names the drug for 184 of them, across 8 drugs with 11 or more claims each, at $490,669 in total drug cost. In 2023, CMS named 123 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Smitha Menon for performance year 2024, reported through an alternative payment model (APM). Smitha Menon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Smitha Menon as offering telehealth.

Dmand AI links 10 papers to Smitha Menon, published from 2015 to 2023. 2015 was the busiest year, with 2. The most frequent topics are Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung and Lung Neoplasms. Smitha Menon's most frequent co-authors are Grace K. Dy, MD, Aminah Jatoi, MD and Gulrayz Ahmed, MD.

Dmand AI links Smitha Menon to 10 clinical trials, 3 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung. SWOG Cancer Research Network sponsors the most, 5.

CMS Open Payments shows 2 general payments to Smitha Menon from 2 drug and device companies from 2016 to 2018. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $118.